AEON Biopharma, Inc. has made a significant move by amending its Two-Year Milestone Warrants, which is expected to enhance its financial position. The company has reduced the exercise price of these warrants from $0.3221 to $0.20 per share of common stock. This change is designed to encourage more holders to exercise their warrants, potentially generating approximately $6.2 million in gross proceeds.

On November 2, 2026, AEON Biopharma entered into the Warrant Amendment with holders representing at least 67% of the shares of common stock and pre-funded warrants. The amendment applies to all outstanding Two-Year Warrants, whether or not the holder executed the amendment. Aside from the reduced exercise price, all other terms of the Two-Year Warrants remain unchanged, including their expiration date.

AEON Biopharma, based in Aliso Viejo, California, operates in the pharmaceutical preparations sector, as classified under SIC 2834. The company trades on the NYSE under the ticker symbol AEON. Its recent filings include a prospectus supplement that updates the terms of the warrants and their expected proceeds.

According to the filing, as of October 30, 2026, there were 71,517,020 shares of AEON common stock outstanding. The amendment to the warrants was prompted by a recent announcement from the U.S. Food and Drug Administration, which indicated that the company's ABP-450 could advance toward a Biologics License Application. This development triggered the accelerated expiration of the Two-Year Warrants, which are set to expire on November 16, 2026.

As AEON Biopharma moves forward, it anticipates that the reduced exercise price will lead to increased participation from warrant holders. This strategy not only aims to bolster the company's finances but also reflects a broader trend in the pharmaceutical industry as companies adjust their financial instruments to better navigate market challenges.

The filing does not specify what happens next for AEON Biopharma, but the company will likely continue to monitor the exercise of these warrants closely.